RELAXIN AS AN INDEPENDENT RISK FACTOR PREDICTING MORTALITY

WIPO Patent Application WO2004106940

A3

Disclosed are methods of characterising life expectancy of human individuals on the basis of measured relaxin levels. In one aspect of the invention the human individuals are end-stage-kidney-disease patients.

WO/2005/094200	BIOMARKERS FOR DIFFERENTIATING BETWEEN TYPE 2 AND TYPE 2 DIABETES
JP2000510001	[Title of the Invention] A transgenic animal having a fragmented NPY Y1 receptor gene.
JPS5221891	IMPROVED ANALYTICAL METHOD

STASCH JOHANNES-PETER (DE)
GEHRMANN MATHIAS (DE)
HOCHER BERTHOLD (DE)

PCT/EP2004/005599

April 07, 2005

May 25, 2004

Click for automatic bibliography generation  

BAYER HEALTHCARE AG (DE)
STASCH JOHANNES-PETER (DE)
GEHRMANN MATHIAS (DE)
HOCHER BERTHOLD (DE)

G01N33/74; (IPC1-7): G01N33/74

DSCHIETZIG THOMAS ET AL: "The pregnancy hormone relaxin is a player in human heart failure", FASEB JOURNAL, vol. 15, no. 12, October 2001 (2001-10-01), pages 2187 - 2195, XP002195177, ISSN: 0892-6638
YEUN J Y ET AL: "C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients.", AMERICAN JOURNAL OF KIDNEY DISEASES: THE OFFICIAL JOURNAL OF THE NATIONAL KIDNEY FOUNDATION. UNITED STATES MAR 2000, vol. 35, no. 3, March 2000 (2000-03-01), pages 469 - 476, XP008024225, ISSN: 1523-6838
FERNANDEZ-REYES MARIA JOSE ET AL: "Inflammation and malnutrition as predictors of mortality in patients on hemodialysis", JN JOURNAL OF NEPHROLOGY, vol. 15, no. 2, March 2002 (2002-03-01), pages 136 - 143, XP002260579, ISSN: 1121-8428

View/Download PDF      PDF Help

Previous Patent: METHOD FOR THE LINKAGE OF BIFUNCTIONAL CHELATING AGENTS AND (RADIOACTIVE) TRANSITION METAL COMPLEXES...

Next Patent: SECRETED POLYPEPTIDE SPECIES ASSOCIATED WITH CARDIOVASCULAR DISORDERS